AMPLIA THERAPEUTICS LTD

Amplia Therapeutics’ shares fall 3.7%, trading below its 200‑day MA; investors eye pipeline milestones, partnerships, and regulatory progress for a potential rebound.

Amplia Therapeutics climbs 1.25% as its immuno‑oncology pipeline fuels hope, but still lags a 200‑day average—watch for next breakthrough and equity moves.

Amplia Therapeutics stock flat as it drops 36% since last month, amid biotech volatility – see market details, peer comparison and future outlook.